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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) offers
the hope of cure for certain lethal malignant and nonmalig-
nant diseases, characterized by defective hematopoietic and
immune function, through the generation of a new hemato-
poietic system [1]. The indications of allogeneic BMT are
being investigated in other clinical situations such as
autoimmune disease [2] and the induction of tolerance for
organ transplantation [3]. The broad potential of allogeneic
BMT has not been achieved mainly because of graft-versus-
host disease (GVHD), a life-threatening complication asso-
ciated with the procedure [4]. Although ideally the inci-
dence of clinically significant acute GVHD could be
controlled [5,6], in general, prophylaxis and therapy of
GVHD remain unsatisfactory. The mortality rate can be as
high as 50% of patients who develop GVHD [4]. Therefore,
alternative approaches for prevention and treatment of
GVHD are essential. Understanding the mechanisms by
which GVHD prevention occurs may provide clues for new
approaches to prevent or treat this disease.
Rapamycin is a natural macrolide produced by a fila-
mentous bacterium Streptomyces hygroscopicus [7] and has
been shown to be highly effective in prevention of GVHD,
resulting in indeﬁnite GVHD-free long-term survival after
short-term treatment [8,9]. Although it is clear that rapa-
mycin blocks signal transduction mediated by interleukin
(IL)-2 and other cytokines [10-12] and the Ca2+-indepen-
dent CD28/CTLA-4–induced costimulatory pathway [13],
these mechanisms of action do not explain why the GVHD-
reactive T cells remain unresponsive after rapamycin with-
drawal, because the half-life of rapamycin in the circulation
is only 4 to 6 hours [14]. The mechanisms of rapamycin-
induced long-term solid organ allograft survival have been
carefully studied [15] and seem to be related to T-cell desen-
sitization due to prolonged engagement of the T-cell recep-
tor (TCR) by alloantigens. This mechanism is not necessar-
ily the same in GVHD prevention.
In this study, the cellular mechanisms of GVHD-free
long-term survival mediated by rapamycin were investigated
in a murine model across a minor histocompatibility barrier.
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ABSTRACT
Understanding the cellular mechanisms that lead to graft-versus-host disease (GVHD) may lead to alternative
approaches in the prevention or therapy of this disease process. In this manuscript, we investigated the mechanisms
of action of the immunosuppressive drug rapamycin for the prevention of GVHD. GVHD-free long-term survival
was achieved in BALB/c (H2d, Mls-2a, Mls-3a) recipients of B10.D2/nSnJ (H-2d, Mls-2a, Mls-3a) bone marrow and
spleen cells after a 30-day course of high-dose rapamycin (5 mg/kg per day). Low responses to recipient and third-
party cells in a mixed lymphocyte reaction (MLR) were observed as well as decreased mature T-cell numbers in the
spleen. This low response was not due to defective interleukin (IL)-2 production, because exogenous IL-2 did not
improve the responses in the MLR. However, GVHD-free long-term survival was associated with a large number of
infiltrating mononuclear cells in the target organs of GVHD. This observation suggested the possibility that these
cells were responsible for suppressing the immune response. Regulatory cells, which could suppress both antirecipi-
ent and third-party responses in vitro, were demonstrated to be present in the spleens of these GVHD-free long-
term survivors. These results suggest that in addition to impaired cellular immune function, the presence of non-
specific regulatory cells (ie, suppression) may contribute to maintenance of GVHD-free long-term survival induced
by short-course rapamycin.
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A short-term treatment course with high-dose rapamycin
(5 mg/kg per day) for 30 days following BMT protected all of
the recipients from developing GVHD up to 160 days after
transplantation. Of interest, mice surviving for the long term
without GVHD demonstrated large numbers of inﬁltrating
mononuclear cells in the usual target organs of GVHD. The
presence of these mononuclear cells in the absence of histolog-
ical evidence of acute GVHD suggests the possibility of regula-
tory cells. These regulatory cells, able to suppress both antire-
cipient and third-party responses in vitro, were demonstrated
to be present in the spleens of these GVHD-free long-term
survivors. These results suggest that in addition to impaired
cellular immune reconstitution, the presence of nonspeciﬁc
regulatory cells (ie, suppression) may contribute to mainte-
nance of GVHD-free long-term survival induced by short-
course rapamycin.
MATERIALS AND METHODS
Animals
B10.D2/nSnJ (H2d, Mls-2b, Mls-3b) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME).
BALB/c (H2d, Mls-2a, Mls-3a) and C57BL/6 (H2b) mice
were obtained from the speciﬁc pathogen–free colonies of
Dr. Robert Kallman, Department of Radiology, Stanford
University School of Medicine, Stanford, CA. Only female
mice were used in this study.
GVHD Model
Via the tail vein, 10  106 bone marrow and 100  106
spleen cells in 0.5 mL plain RPMI 1640 medium from
B10.D2 mice were injected into lethally irradiated (8.0 Gy)
BALB/c recipients. It was previously shown that this proto-
col induced the most severe form of GVHD [16]. Donor
mice were 8 to 14 weeks old and recipient mice were 12 to
13 weeks old at the time of transplantation. All experiments
were performed according to federal and Stanford Univer-
sity guidelines. Recipients were monitored daily for clinical
signs of GVHD by body weight and the extent of skin
changes (hair loss and erythema) as scored on a cumulative
severity scale from 0 (minimum) to 8 (maximum): head 1,
neck 1, back (1/3, 2/3, 3/3) 1 to 3 and front (1/3, 2/3, 2/3) 1
to 3, as described [16-19]. Mortality was also recorded daily.
Ear skin biopsies were routinely taken on days 30, 70, 100,
and 150 after transplantation and when the mice were mori-
bund. Histological changes were assessed as described [20].
Drugs and Treatment
Rapamycin was supplied as a pure compound in powder
form from Wyeth-Ayerst Research (Princeton, NJ) and pre-
pared fresh daily by suspending in 0.2% carboxymethylcellu-
lose (CMC) and thoroughly homogenized before administra-
tion. Three doses of rapamycin were used to treat the animals:
low dose, 0.5 mg/kg per day; medium dose, 1.5 mg/kg per
day; and high dose, 5 mg/kg per day. cyclosporine A (Sandim-
mune injection: 50 mg/mL cyclosporine A, 33% ethanol, 65%
cremophor) was obtained from Sandoz Pharmaceuticals (East
Hanover, NJ) and diluted in phosphate-buffered saline (PBS).
All drugs and CMC control were injected intraperitoneally
once a day for 30 days beginning on the day of BMT. The vol-
ume of drug suspension given was 0.01 mL/g.
Histology and Immunohistochemistry
Specimens for regular histology were ﬁxed in 10% for-
malin, embedded in parafﬁn, and stained with hematoxylin-
eosin [21]. A total of 5 high-power (400) ﬁelds per sample
were studied to quantitate the numbers of infiltrating
mononuclear cells. Portions for immunohistochemical analy-
sis were embedded in Tissue-Tek OCT compound (Miles,
Elkhart, IN). Frozen tissue blocks were kept at –70°C before
sectioning. Sections were cut at 6 µm, picked up on glass
slides, and ﬁxed in absolute acetone at –20°C for 10 minutes.
The sections were incubated at room temperature sequen-
tially in primary antibody (anti-CD3: 145-2c11, anti-CD4:
RM4-5, anti-CD8: 53-6.7, anti-TCR: H57-597; PharMin-
gen, San Diego, CA), in biotinylated secondary antibody
(mouse anti-hamster immunoglobulin [Ig] G for CD3 and
TCR, goat anti-rat Ig for CD4 and CD8; PharMingen)
and in an optimal dilution of avidin-biotin-peroxidase com-
plexes (Vector, Burlingame, CA). Sections were washed in
PBS for 10 minutes after each step of the incubation. Posi-
tively stained cells were visualized with diaminobenzidine,
0.01% H2O2, and 0.3% sodium azide in 0.05 mol/L Tris
buffer, pH 7.6. Slides were counterstained with Meyer
hematoxylin and mounted. To quantitate the percentages of
positive cells, 300 total cells were counted for each slide.
Repeated analysis in a blinded fashion yielded results within
10% of initial scores.
Mixed Lymphocyte Reaction
A total of 5  105 responder spleen cells were plated
in flat-bottom 96-well culture plates with 5  105 irradi-
ated (10 Gy) spleen stimulator cells in a final volume of
200 µL. After 96 hours of incubation at 37°C and 5%
CO2, cultures were pulsed with 1 µCi [
3H]thymidine per
well and harvested 16 hours later. Triplicate cultures were
set up for every cell population tested. Culture medium
was RPMI 1640 supplemented with 10% prescreened fetal
calf serum, 2 mmol/L L-glutamine, 50 µmol/L 2-mercap-
toethanol, 100 U/mL penicillin, and 100 µg/mL strepto-
mycin. This medium was used for all the subsequent in
vitro studies.
Cytotoxic T Lymphocyte Assay
The assay was designed to enhance the sensitivity to
detect the cytotoxic T lymphocyte (CTL) against minor his-
tocompatibility antigens as described [22]. Briefly, graded
numbers of responder cells were plated with 5  105 irradi-
ated (10 Gy) stimulator cells. Plates were cultured in a 37°C,
5% CO2 incubator for 10 days. Recombinant human IL-2 
(5 U/mL) (Cetus Immune, Emeryville, CA) was added on
days 3 and 6 after initiation of the culture. The cells were
tested in situ for lysis of 51Cr-labeled day 2 concanavalin A
blast cells. After 4 hours of culture, supernatant was taken
out and counted in a  counter. In each experiment, cultures
were tested in parallel for lysis of irrelevant targets to ensure
antirecipient specific killing. The percentage of specific
release was calculated as follows.
experimental release – 
% speciﬁc release =
spontaneous release        
 100
maximal release –
spontaneous release
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Spontaneous release was obtained by incubating target
cells with stimulator cells only. Maximal release was obtained
after treatment with 2% Nonidet P-40.
Coculture Assay
The assay was performed as described [23]. Brieﬂy, spleen
cells were added as cocultured cells to the 1-way mixed lym-
phocyte reaction (MLR) described in previous sections.
Cocultured cells were irradiated (10 Gy) and added in a ratio
of 1:1 to responder cells. Spleen cells from B10.D2 mice pre-
viously immunized to BALB/c (details in “Positive Control”)
and naive B10.D2 mice were used as responder cells in MLR
against recipient and third-party cells, respectively. The per-
centage of suppression was calculated according to the fol-
lowing formula. 
% suppression = (1 – 
cpm with cocultured cells
)  100
cpm without cocultured cells
Flow Cytometric Analysis
A total of 1  106 spleen cells were stained with ﬂuores-
cence–conjugated antibodies and incubated on ice for 30 min-
utes. Cells were washed and resuspended in 0.2 mL ﬂuores-
cence-activated cell sorter (FACS) buffer (PBS with 0.1% bovine
serum albumin and 0.01% sodium azide) for analysis. Pheno-
typic analysis was performed with a FACScan (Becton Dickin-
son, San Jose, CA), using monoclonal antibodies to CD3, CD4,
CD8, TCR, B220, and NK1.1 (PharMingen).
Positive Control
B10.D2 mice were injected intraperitoneally with 5  107
spleen cells from BALB/c mice in plain RPMI 1640 [16,24].
Spleen cells were harvested 21 days later as positive control
(termed “immune B10.D2”). Because GVHD-free long-term
survivors have been exposed to recipient antigens before,
immune B10.D2 was thought to be a better control than naive
B10.D2. All mice with GVHD had died and were not avail-
able to serve as a control group.
Figure 1. Short-term treatment with rapamycin (RPM) was highly effective in prophylaxis of murine graft-versus-host disease (GVHD), and GVHD-
free long-term survival was achieved in high-dose RPM-treated mice. A total of 10  106 bone marrow cells and 100  106 spleen cells from B10.D2
mice were transplanted into lethally irradiated (8.0 Gy) BALB/c recipients. Recipient mice received treatment daily for 30 days starting on the day of
transplantation. Data were pooled from 2 similar experiments. A, Incidence of clinical GVHD. Clinical GVHD was assessed daily by skin changes (hair
loss and erythema) and loss of body weight. Of 10 mice treated with medium-dose RPM, 3 developed slight clinical GVHD and recovered from the
GVHD process without any treatment. None of 10 mice treated with high-dose RPM developed clinical GVHD. B, Mean body weight curve. There
was only 1 surviving mouse in the carboxymethylcellulose (CMC) control group after day 84. C, Actuarial survival from lethal GVHD. The median
survival times in all 3 RPM-treated groups were more than 160 days and are superior (P < .00001) to the CMC control group and comparable with the
cyclosporine A (CsA) (50 mg/kg per day) group (P > .05).
(n = 10)
(n = 5)
(0.5 mg/kg/d, n = 5)
(1.5 mg/kg/d, n = 10)
(5 mg/kg/d, n = 10)
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Statistical Analysis
Group-wise comparison was made by Student t test.
Survival data were analyzed by log-rank test.
RESULTS
Rapamycin Highly Effective in Prophylaxis of Murine
GVHD
Daily administration of rapamycin for the ﬁrst 30 days
after allogeneic transplantation protected BALB/c recipients
of B10.D2 bone marrow and spleen cells from lethal GVHD.
Mice treated with low-dose rapamycin alone (0.5 mg/kg per
day) had a delayed onset of clinical GVHD compared with
CMC control mice. Of 10 mice treated with medium-dose
rapamycin (1.5 mg/kg per day), 3 developed slight clinical
GVHD. The other 7 mice in this group did not develop any
signs of clinical GVHD with follow-up of 160 days after
transplantation. Nevertheless, skin biopsy (ear) on day 150
after transplantation demonstrated that all of the mice in the
medium-dose rapamycin group developed histological
GVHD documented by the presence of vacuolated cells in
the epidermis. None of the 10 mice treated with high-dose
rapamycin (5 mg/kg per day) developed either clinical or his-
tological evidence of GVHD during the observation period
of 160 days after transplantation (Figure 1A). Treatment with
all 3 doses of rapamycin decreased the overall disease severity
as measured by the disease severity scores (data not shown)
and by the weight curve of animals that underwent transplan-
tion (Figure 1B), resulting in significantly higher survival
rates compared with CMC control (P < .0001). The survival
of the rapamycin groups was comparable with that of mice
treated with cyclosporine A, 50 mg/kg per day (Figure 1C).
However, GVHD-free long-term survival was achieved only
in the high-dose group. Rapamycin syndrome, described by
Blazar et al. [9], was observed in 1 of 10 recipients in the
high-dose rapamycin group but none of the recipients in the
lower-dose groups. Subsequent attempts to study the mecha-
nisms of rapamycin-induced GVHD-free long-term survival
Figure 2. More inﬁltrating cells were observed in the skin of rapamycin (RPM)-treated mice in a dose-dependent manner on day 30 after trans-
plantation (hematoxylin and eosin staining, 400). Representative skin changes from the animals of different groups are shown. A, Control mouse
treated with carboxymethylcellulose (CMC). B, Control mouse treated with cyclosporine A (CsA) 50 mg/kg per day. C-E, Mice treated with 3 dif-
ferent doses of RPM: low dose, 0.5 mg/kg per day (C); medium dose, 1.5 mg/kg per day (D); and high dose, 5 mg/kg per day (E). Prominent inﬁl-
trating mononuclear cells and angiogenesis were noted in the skin of RPM-treated mice in a dose-dependent manner, without any evidence of histo-
logical graft-versus-host disease (vacuolated cells and dyskeratosis). Data in the table are the results from immunohistochemistry study of these
inﬁltrating mononuclear cells. A total of 300 cells were counted for each slide. Results represent means from 3 animals per group.
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were carried out in the mice without rapamycin syndrome in
the high-dose rapamycin-treated group (they were termed
“GVHD-free long-term survivors”). All animals were full
donor chimeras (data not shown).
Infiltrating Mononuclear Cells Observed in Skin of
Rapamycin-Treated Mice
Histological analysis of skin (ear) from B10.D2 →
BALB/c recipients on day 30 after transplantation demon-
strated prominent inﬁltrating mononuclear cells (CMC con-
trol: 54.6 ± 7.8/ﬁeld; rapamycin, 5 mg/kg: 206.9 ± 76.6/ﬁeld;
5 animals per group; P < .0001) and angiogenesis in the skin
of rapamycin-treated recipients in a dose-dependent manner
(Figure 2A-E). The numbers of mononuclear cells increased
in a dose-dependent manner: the higher the rapamycin
dose, the more infiltrating cells were apparent (low dose:
72.1 ± 18.6; medium dose: 122.8 ± 29.4; high dose: 206.9 ±
76.6; 5 animals per group; P < .05 between groups). The
infiltrating mononuclear cells decreased gradually after
rapamycin withdrawal. Immunohistochemical studies on the
inﬁltrating mononuclear cells of the high-dose rapamycin-
treated mice demonstrated that 62% of them were CD3+,
37% were CD4+, and <2% were CD8+, suggesting that
about half of the CD3+ inﬁltrating cells belonged to the cells
with CD3+CD4–CD8– phenotype.
Decreased In Vitro Antirecipient and Third-Party
Responses in GVHD-Free Long-Term Survivors
Treatment with high-dose rapamycin resulted in the long-
term survival of B10.D2 → BALB/c recipients in the absence
of GVHD, indicating that GVHD-reactive T cells were silent
to the recipient antigens. The low antirecipient responsiveness
was documented by the results from both MLR (Table 1) and
CTL assay (Figure 3) compared with immune B10.D2. Spleen
cells from these GVHD-free long-term survivors also had a
low response against third-party cells (Table 1). Naive B10.D2
did not respond to recipient (BALB/c) in MLR as previously
reported [25]. These results indicate that the low response in
GVHD-free long-term survivors induced by high-dose
rapamycin was not antigen-speciﬁc. Moreover, the addition of
recombinant human IL-2 did not change the response, sug-
gesting that this defect was not due to clonal anergy induced
by a defect of IL-2 production (data not shown).
Nonspeciﬁc unresponsiveness in these GVHD-free long-
term survivors induced by high-dose rapamycin could be due
simply to impaired immune reconstitution. Flow cytometric
analysis was performed to determine whether this was the
case. As shown in Table 2, long-term survivors treated with
high-dose rapamycin had fewer CD3+, CD3+CD4+,
CD3+CD8+, and TCR+ cells than did immune B10.D2 and
naive controls, which could contribute to the low antirecipi-
ent and third-party responses. The percentages of T cells and
T-cell subsets in the medium-dose rapamycin group were
higher than in the high-dose rapamycin group but were lower
than in both naive and immune B10.D2. There was no
unique increase in the phenotypes tested (CD3+, CD3+4+,
CD3+CD8+, TCR+, B220+, NK1.1+) except for a slight
increase in TCR+ CD4–CD8– cell population in the spleens
from high-dose rapamycin-treated, GVHD-free, long-term
BMT survivors compared with all other groups.
Suppression of Antirecipient and Third-Party MLR in
GVHD-Free Long-Term Survivors
The 5  105 irradiated (10 Gy) spleen cells from the
high-dose rapamycin-treated long-term BMT survivors sup-
pressed the MLR against recipient and third-party cells
(immune B10.D2 versus BALB/c or naive B10.D2 versus
C57BL/6 with 5  105 responder cells and 5  105 irradi-
ated [10 Gy] stimulator) by 83.4% and 92.5%, respectively
Table 1. Decreased Antirecipient and Third-Party Responses of High-Dose
Rapamycin-Treated GVHD-Free Long-Term Survivors in Mixed Lymphocyte
Reaction*
 cpm
Third Background,
Group Recipient party cpm
Naive B10.D2 0.4 ± 0.2 21.1 ± 8.6 2.2 ± 0.4
Immune B10.D2 7.5 ± 3.4 29.3 ± 4.6 2.1 ± 0.2
High-dose rapamycin 2.1 ± 0.4†‡ 4.7 ± 2.0§ 0.7 ± 0.1
*A total 5  105 spleen cells were plated with 5  105 irradiated
(10 Gy) stimulating spleen cells from normal mice in a 96-well ﬂat-bot-
tom plate. After 96 hours of incubation, cultures were pulsed with
1 µCi/well [3H]thymidine for an additional 16 hours before har-
vesting. Data are proliferation (cpm  103) subtracted from syngeneic
control, representing mean ± SD of cpm from 3 to 5 mice of each
group. SDs were <15% of the mean from triplicate cultures. GVHD
indicates graft-versus-host disease;  cpm, change in cell count per
minute.
†P > .05 versus naive B10.D2. 
‡P < .05 versus immune B10.D2.
§P < .01 versus immune B10.D2.
P < .05 versus naive B10.D2. 
Figure 3. Decreased antirecipient cytotoxic T-lymphocyte activity. A
total of 5  105 responder cells were plated with 5  105 irradiated
stimulators from recipient mice. Interleukin-2, 5 U/mL, was added on
day 3 and day 6 after initiation of the culture. On day 10, cultures were
assayed for cytotoxicity on recipient strain day 2 concanavalin A blast
cells in a 4-hour chromium release assay. Nonspeciﬁc release against
irrelevant antigens was performed to ensure the speciﬁcity at each time.
Spontaneous release was always <15% of maximum release. Results are
means ± SD of speciﬁc releases from 3 to 5 mice in each group. RPM
indicates rapamycin.
Sp
ec
iﬁ
c 
re
le
as
e 
of
 c
hr
om
iu
m
 (%
)
Effector:Target
B.J. Chen et al.
534
(Figure 4). Spleen cells from the recipients of medium-dose
rapamycin, recipients of cyclosporine A 50 mg/kg per day,
naive B10.D2, and immune B10.D2 controls had no sup-
pressive effects, but rather enhanced the response in the
MLR against recipient cells. Spleen cells from naive
B10.D2, immune B10.D2, the recipients of cyclosporine A
50 mg/kg per day and medium-dose rapamycin all demon-
strated some suppression of the MLR against third-party
cells. However, the degree of suppression was much less
compared with that of recipients of high-dose rapamycin
(P < .05, P < .01, P < .001, and P < .01, respectively).
DISCUSSION
Absence of antigen-speciﬁc T cells, or clonal deletion, has
been shown to be an important mechanism for the induction
of tolerance to self-antigens and bacterial superantigens [26-
28]. Clonal anergy has been shown to be responsible for toler-
ance in many models [29,30]. Exogenous IL-2 was reported to
restore proliferation of anergic T-cell clones [31,32] and some
in vivo–generated anergic T cells [29,33]. In our model,
exogenous recombinant IL-2 failed to rescue the responses of
GVHD-free long-term survivors against both recipient and
third-party cells. T-cell desensitization due to prolonged
engagement of TCR by persistent alloantigen could also be
responsible for clonal anergy [15,34]. This mechanism is less
likely to explain the low responses induced by rapamycin in
our model, because GVHD developed late in the low-dose or
medium-dose rapamycin-treated mice.
Active immune suppression mediated by regulatory cells
has been proposed to be involved in maintenance of tolerance
[35,36]. Cellular approaches using syngeneic or autologous
bone marrow have been used successfully to reverse signiﬁ-
cant GVHD in allogeneic BMT [37,38]. Potential mecha-
nisms by which such cells can modulate immune responses
include natural suppressor [39-42] and veto activity [39,40].
Natural suppressor cells are potent nonspeciﬁc inhibitors of
immune responses. Veto cells are capable of preventing the
generation of CTL in a major histocompatibility
complex–restricted fashion. Several cell phenotypes associ-
ated with suppressive activity have already been identiﬁed in
mice, including null cells [40], TCR+CD4–CD8– [41],
Thy-1+ NK1 asialo GM-1+ CD3+ [39], TCR+ NK1.1+ [42],
and CD4+ [43]. Successful cloning of antigen-speciﬁc [43] and
nonspeciﬁc [42,44] regulatory cells furnishes direct evidence
of the existence of regulatory cells (ie, suppression).
Dose-dependent emergence of the inﬁltrating mononu-
clear cells in the skin of the rapamycin-treated mice that did
not develop GVHD suggests that these infiltrating
Figure 4. Suppression of antirecipient and third-party mixed lympho-
cyte reaction (MLR) by spleen cells from graft-versus-host disease
(GVHD)-free long-term survivors. A total of 5  105 irradiated
(10 Gy) spleen cells from different groups were added to either
immune B10.D2 versus BALB/c MLR or naive B10.D2 versus
C57BL/6 MLR with 5  105 responder and 5  105 irradiated (10 Gy)
stimulator cells per well. Cultures were pulsed with [3H]thymidine 1 µCi
per well after 96 hours of incubation and harvested 16 hours later.
Results are given as means ± SD of triplicate cultures and represent 1 of
3 separate experiments with comparable results. The 10 Gy–irradiated
putative suppressor cells did not respond to concanavalin A (stimula-
tion index <2). *P < .01, †P < 0.001 versus medium control. The back-
ground cpm for immune B10.D2 and naive B10.D2 were 2630 and
1799, respectively. , naive B10.D2; , immune B10.D2; , cyclo-
sporine A 50 mg/kg; , medium-dose rapamycin (RPM); , high-dose
RPM; , medium control. CPM indicates counts per minute.
Table 2. Flow Cytometric Analysis of Spleen Cells From Long-Term Bone Marrow Transplantation Survivors*
Naive B10.D2 Immune B10.D2 CsA Mid-Dose RPM High-Dose RPM
CD3+ 30.1 ± 1.1 36.9 ± 1.9 13.9 ± 1.9 16.6 ± 1.2 11.5 ± 1.4†‡
CD3+CD4+ 20.0 ± 0.7 22.2 ± 1.6 7.9 ± 1.0 8.8 ± 0.1 4.6 ± 0.4†
CD3+CD8+ 10.1 ± 0.7 14.7 ± 0.7 6.0 ± 1.9 7.8 ± 1.0 5.1 ± 0.9†‡
TCR+ 38.6 ± 2.4 43.0 ± 2.3 17.0 ± 2.2 18.0 ± 0.6 18.0 ± 1.6†‡¶
B220+ 59.9 ± 3.5 53.7 ± 1.8 77.8 ± 3.1 75.2 ± 0.3 60.5 ± 3.5†§
NK1.1+ 13.8 ± 1.5 18.1 ± 1.3 8.1 ± 3.3 15.4 ± 1.3 16.7 ± 1.4†§¶
TcR+ CD4–CD8– 2.6 ± 0.5 5.5 ± 0.7 4.2 ± 1.3 4.8 ± 0.7 6.4 ± 0.4†¶
*Spleen cells from the long-term bone marrow transplantation survivors shown in Figure 1 were analyzed by flow cytometer. Results are
expressed as mean percentages ± SD of spleen cells from 2 to 5 mice of each group. CsA indicates cyclosporine A; RPM, rapamycin.
†P < .05 versus other groups except those indicated in following footnotes.
‡P > .05 versus CsA group.
§P > .05 versus naive B10.D2.
P > .05 versus immune B10.D2.
¶P > .05 versus medium-dose RPM.
†
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mononuclear cells belong to a suppressive cell population
rather than to a population of effector cells of GVHD.
Blazar et al. [9] also observed the increase of a double nega-
tive T-cell population, which has been previously reported
to belong to a nonspeciﬁc regulatory cell population [44,45].
To determine the mechanisms of prevention of GVHD with
rapamycin, we performed a coculture assay and found that
cells with suppressive activity to both antirecipient and
third-party response exist in high-dose rapamycin-treated
long-term survivors but not in cyclosporine A–treated mice
(Figure 4). These cells did not appear to destroy skin tissue.
These regulatory cells appear to be real, because we
excluded the following possible nonspeciﬁc suppression: (1)
cocultured cells were irradiated before culture and therefore
could not proliferate, so the suppression was unlikely to be
due to rapid depletion of essential nutrients, acceleration of
responses by adding helper cells, and destruction of stimula-
tor cells by adding CTL [46]; (2) the suppression of antire-
cipient responses was not due to the interference of respon-
der-stimulator cell-to-cell contact because the addition of
cocultured cells from all the control groups increased rather
than decreased the MLR response; (3) it is unlikely that the
suppression was due to the excess IL-2 receptor in the
cocultured cells that could absorb IL-2 because additional
IL-2 did not restore responsiveness [47]; and (4) the sup-
pression was unlikely to be due to residual rapamycin
because the half-life of rapamycin in the circulation in the rat
is only 4 to 6 hours [14]. Our data suggest that rapamycin is
able to regulate immune responses through the generation of
a population of cells that suppress the immune response.
Our model suggests that rapamycin prevented GVHD
not only because the responsiveness of GVHD-reactive
T cells was directly inhibited by rapamycin, but also because
antigen nonspeciﬁc regulatory cells (ie, suppression) were gen-
erated by rapamycin in a dose-dependent manner. These reg-
ulatory cells might interfere with the regeneration of mature
T lymphocytes. Animals treated with the high-dose rapamycin
induced enough regulatory cells to allow the mice in this
cohort to survive GVHD-free in the period we monitored.
Persistent presence of regulatory cells might also contribute to
other mechanisms leading to the maintenance of more stable
unresponsiveness, like clonal deletion in the current study
(data not shown). Further analysis of the speciﬁc cell types
involved in this suppressive activity is warranted. Because pre-
vention and treatment of GVHD remains problematic, the
potential to control GVHD by regulatory cells induced by
rapamycin may be useful in developing alternative approaches
to GVHD. However, it needs to be pointed out that nonspe-
cific suppressor cells might also increase the incidence of
opportunistic infection, as previously suggested by others [48].
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